Not everyone grieves genetic loss. This piece explores the complex, personal journey of donor conception—and why your ...
Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...
Durham-based Atsena Therapeutics has raised $150 million to advance gene therapies for preventing or reversing types of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback